Topic Discussed : Mergers and acquisiton landscape in the Lifescience Industry
Speaker : Khushbu Jain
Key Takeaways:
Pharma companies are seeking radical and immediate growth through M&A. Conversely, we can expect a lower volume of total deals but a higher average deal value
Diagnostic and research tools segments on the other hand can extract value from inorganic growth by thinking beyond data curation and more about deriving & utilizing insights
On that note, I hope you enjoyed this session.
Please join us for future podcasts and become a member of our Leadership Council
Email us at [email protected]. Thank you for your time.
Related Keywords: Mergers and Acquisitions in Life Science, mega-mergers, mega-acquisitions, M&A in pharma, M&A in biopharma, M&A in contract research organizations, M&A in contract development and manufacturing organizations, M&A in diagnostics, cell and gene therapy, patient engagement 2.0, patient centricity, connected health, Medication Adherence, Remote Monitoring, Tele Health, Direct to Consumer Genetic Testing, Companion Diagnostic & Biomarker Discovery, Liquid Biopsy, Cell and Gene Therapy, Pharmacogenomics, Artificial Intelligence, Big Data, RWE, Blockchain, IIoT, Outsourcing, X-as-a-Service, Data Monetization, Private equity investment, FAMGA, non-traditional healthcare players, fortune 50, Charles River, Eurofins Scientific, ICON Plc, IQVIA, LabCorp, Parexel, PPD, PRA Health, Syneos Health (INC Research and inVentiv Health), Wuxi Apptech, AMRI, Patheon, Cambrex, Catalent, Lonza, Piramal, Recipharm, Samsung Biologics, Siegfried, BioXcellence , Bio-Rad, Thermo Fisher, Perkin Elmer, Agilent Technologies, Qiagen, Danaher, Sysmex, Roche Diagnostics, Illumina, Becton Dickinson, bioMerieux, Pfizer, Roche, AstraZeneca, GSK, Novartis, Merck, Sanofi, AbbVie, Bristol-Myers Squibb, Jefferies Financial Group, Montagu Private Equity, Nordic Capital, Capstone, Catapult Partners
Website: www.frost.com
Hosted on Acast. See acast.com/privacy for more information.